MAPK pathway

Overview

The mitogen-activated protein kinase (MAPK) pathway is a conserved intracellular signaling cascade that transduces extracellular cues into cellular responses such as proliferation, differentiation, survival, stress adaptation, and senescence. In biomedical research, “MAPK pathway” commonly refers to a family of related kinase modules, including ERK, JNK, and p38 signaling branches, that regulate gene expression and cell fate decisions in normal physiology and disease.

Dysregulation of MAPK signaling is a well-established feature of cancer and other pathologic states. In the recent studies summarized here, MAPK pathway activation was linked to aggressive thyroid cancer, sarcoma, and therapy resistance, while pathway inhibition or modulation was explored as a strategy to restore radioiodine avidity, sensitize tumors to ferroptosis, or alter inflammatory and senescence-related phenotypes. The pathway was also examined in nonmalignant cells, where it appeared to mediate protective or stress-related responses downstream of receptors such as GPR30 and upstream regulators such as CACNG6.

Focus of Latest Publications

Recent publications have examined the MAPK pathway as a therapeutic and mechanistic node across several disease contexts, especially cancer and inflammatory disorders. In thyroid cancer, short-course MAPK pathway inhibition has been evaluated as part of a redifferentiation strategy for radioiodine-refractory differentiated thyroid cancer, combined with individualized dosimetry-guided radioiodine. In aggressive thyroid cancers, BRAFV600E-driven MAPK activation was linked to ETV5 expression and to activation of the p38/MAPK14 arm of the pathway, suggesting an interconnected signaling network that may contribute to treatment resistance.

Several studies also explored upstream modulators of MAPK signaling. Tranexamic acid was investigated for its potential anti-ageing effects in human dermal fibroblasts, with the study specifically assessing whether it protects against D-galactose-induced senescence via the GPR30/MAPK pathway. In a mouse model of chronic obstructive pulmonary disease induced by cigarette smoke and lipopolysaccharide, Aconitum septentrionale Koelle extract was reported to alleviate disease by modulating the MAPK pathway, supporting a role for MAPK signaling in inflammatory lung injury.

Other publications focused on MAPK pathway involvement in host response and drug action. In carbapenem-resistant Klebsiella pneumoniae pneumonia, tigecycline-loaded M2 macrophage nanoparticles reduced bacterial burden and inflammation, and the authors reported that this effect involved inhibition of calcium influx through downregulation of CACNG6, thereby indirectly modulating the MAPK pathway. In MECP2-dependent cancers, epigenetic drugs were shown to be effective in preclinical models, and the study identified MECP2-induced activation of the MAPK pathway as part of the mechanism, with PAK3 implicated as an important mediator. The work also noted that activated RAS and other MAPK activators could confer resistance to these therapies.

Overall, these studies position the MAPK pathway as a recurring target in translational research, with interventions ranging from small molecules and plant extracts to nanoparticle-based delivery systems and epigenetic drugs. Across the abstracts, MAPK signaling was associated with fibroblast senescence, pulmonary inflammation, thyroid cancer redifferentiation and resistance, bacterial pneumonia, and oncogenic signaling in MECP2-driven tumors.

Key Publications

May Tranexamic acid protects human dermal fibroblasts from D-galactose-induced senescence via the GPR30/MAPK pathway. (Annals of medicine, 2026, PMID 42059427): "to investigate whether TXA protects human dermal fibroblasts from D-galactose-induced senescence via the GPR30/MAPK pathway."
Mar Aconitum septentrionale Koelle extract alleviates cigarette smoke and lipopolysaccharide-induced chronic obstructive pulmonary disease in mice by modulating the MAPK pathway. (Journal of ethnopharmacology, 2026, PMID 41864552): "Aconitum septentrionale Koelle extract alleviates cigarette smoke and lipopolysaccharide-induced chronic obstructive pulmonary disease in mice by modulating the MAPK pathway."
May M2 macrophage-mediated tigecycline nanoparticles for combating CRKP pneumonia via antibacterial and immunomodulatory therapy. (Journal of controlled release : official journal of the Controlled Release Society, 2026, PMID 41819427): "Wefurther confirmed that PT@M2 could inhibit calcium ion influx by downregulating CACNG6, thereby indirectly modulating the MAPK pathway."
May Restoring Radioiodine Avidity in Radioiodine-refractory Differentiated Thyroid Cancer With Genotype-guided MAPK Inhibition and Dosimetry-guided Radioiodine. (Clinical nuclear medicine, 2026, PMID 41686811): "To evaluate the real-world effectiveness and safety of short-course MAPK pathway inhibition, integrated with individualized dosimetry, as a redifferentiation strategy in patients with radioiodine-refractory differentiated thyroid cancer (RAIR-DTC)."
May Role of the ETV5/p38 Signaling Axis in Aggressive Thyroid Cancer Cells. (Molecular cancer therapeutics, 2026, PMID 41544239): "Around 25% of PDTCs and 35% of ATCs carry the BRAFV600E mutation, which constitutively activates the MAPK pathway, a key driver of cell growth."
May MECP2-Dependent Cancers Can Be Targeted by Epigenetic Drugs: A New Role for Epigenetic Cancer Therapy. (Molecular cancer therapeutics, 2026, PMID 41379640): "We then investigated the mechanism of MECP2-induced activation of the MAPK pathway and assessed the effect of drug treatment."